Valuation: Orletto Capital Inc

Market Cap 28.2M 20.37M 20.37M 17.46M 16.36M 14.94M 1.94B 28.48M 193M 75.11M 980M 76.49M 74.83M 3.24B P/E 2024
-22.2x
P/E 2025 -3.7x
Enterprise Value 21.34M 15.42M 15.42M 13.21M 12.38M 11.31M 1.47B 21.55M 146M 56.84M 742M 57.89M 56.63M 2.46B EV / Sales 2024
1.11x
EV / Sales 2025 0.65x
Free-Float
87.96%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 09/06/2025
Director of Finance/CFO - 02/02/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman - 03/06/2024
Director/Board Member - 25/05/2017
Director/Board Member 64 28/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
+3.31%-3.70%+61.03%+103.64% 71.35B
+1.74%+1.06%+49.02%+87.38% 64.17B
+1.09%+22.96%+8.55%-3.03% 28.65B
-0.07%-3.56%-3.45%+467.26% 27.06B
-2.87%+5.74%+55.27%+11.93% 27.33B
+3.98%+4.37%+39.47%-14.65% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
+0.10%+0.19%+8.01%+543.56% 15.96B
+3.98%+6.78%+49.66%+157.94% 14.05B
Average +1.36%+4.46%+59.66%+197.15% 32.04B
Weighted average by Cap. +1.58%+3.31%+55.52%+154.71%

Financials

2024 2025
Net sales 17.82M 12.87M 12.87M 11.03M 10.33M 9.44M 1.23B 17.99M 122M 47.46M 619M 48.33M 47.28M 2.05B 23.59M 17.04M 17.04M 14.6M 13.68M 12.5M 1.62B 23.82M 161M 62.84M 820M 63.99M 62.6M 2.71B
Net income -1.22M -885K -885K -758K -710K -649K -84.35M -1.24M -8.38M -3.26M -42.56M -3.32M -3.25M -141M -6.01M -4.34M -4.34M -3.72M -3.49M -3.19M -414M -6.07M -41.14M -16.02M -209M -16.31M -15.96M -692M
Net Debt -7.62M -5.5M -5.5M -4.72M -4.42M -4.04M -525M -7.69M -52.12M -20.29M -265M -20.66M -20.21M -876M -6.86M -4.95M -4.95M -4.25M -3.98M -3.63M -472M -6.93M -46.92M -18.27M -238M -18.6M -18.2M -789M
Logo Orletto Capital Inc
Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various autoimmune fibroinflammatory diseases with novel therapeutic approaches to targeting unmet medical needs. The Company is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis. It is also involved in the development of cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Its Thykamine is an active lead drug candidate with safety and profiles confirmed in several pre-clinical and clinical studies targeting inflammation. Its cosmeceutical products include R-Spinasome and Purgenesis. The Company’s subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand-name pharmaceutical companies.
Employees
-